Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes
- PMID: 2191189
- DOI: 10.1016/0026-0495(90)90025-8
Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes
Abstract
In order to compare the effects of intraperitoneal (IP) versus subcutaneous (SC) insulin delivery on plasma lipoproteins, lipoprotein cholesterol, triglycerides, and very-low-density lipoprotein (VLDL) metabolism were compared in five type I diabetic patients while they were receiving continuous IP insulin (CIPII) or continuous subcutaneous insulin infusion (CSII). Each therapy regimen was of at least 1 month duration, and patients were treated in random order. Mean daily plasma insulin was lower on CIPII compared with CSII. CIPII was associated with lower VLDL triglycerides and VLDL apolipoprotein (apo) B, and higher high-density lipoprotein (HDL) and HDL3 cholesterol. The decreased VLDL on CIPII appeared to be the result of both decreased production and increased clearance of VLDL apo B. The results suggest that the more physiologic route of insulin therapy (CIPII) is associated with lipoprotein profiles of lower atherogenic potential.
Similar articles
-
Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.Metabolism. 1996 Apr;45(4):430-4. doi: 10.1016/s0026-0495(96)90215-2. Metabolism. 1996. PMID: 8609827 Clinical Trial.
-
Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity.Diabetes Care. 1994 Jan;17(1):6-12. doi: 10.2337/diacare.17.1.6. Diabetes Care. 1994. PMID: 8112191 Clinical Trial.
-
Improved lipoprotein surface and core lipid composition following intraperitoneal insulin delivery in insulin-dependent diabetes mellitus.Diabetes Metab. 1996 Dec;22(6):420-6. Diabetes Metab. 1996. PMID: 8985650 Clinical Trial.
-
Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A systematic review and meta-analysis.PLoS One. 2021 Apr 13;16(4):e0249611. doi: 10.1371/journal.pone.0249611. eCollection 2021. PLoS One. 2021. PMID: 33848314 Free PMC article.
-
Atherogenic profiles in insulin-dependent diabetic patients and their treatment.Eur J Epidemiol. 1992 May;8 Suppl 1:125-8. doi: 10.1007/BF00145363. Eur J Epidemiol. 1992. PMID: 1505649 Review.
Cited by
-
Dyslipidemia of the metabolic syndrome.Curr Cardiol Rep. 2002 Nov;4(6):494-500. doi: 10.1007/s11886-002-0113-6. Curr Cardiol Rep. 2002. PMID: 12379172 Review.
-
Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice.Front Pharmacol. 2021 Feb 19;11:591293. doi: 10.3389/fphar.2020.591293. eCollection 2020. Front Pharmacol. 2021. PMID: 33679386 Free PMC article.
-
Finding the right route for insulin delivery - an overview of implantable pump therapy.Expert Opin Drug Deliv. 2017 Sep;14(9):1103-1111. doi: 10.1080/17425247.2017.1267138. Epub 2016 Dec 7. Expert Opin Drug Deliv. 2017. PMID: 27911116 Free PMC article. Review.
-
Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues.Biochem J. 2004 Jul 1;381(Pt 1):51-7. doi: 10.1042/BJ20040177. Biochem J. 2004. PMID: 15018609 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical